Cubist's 2Q revenue jumps 30% on mainstay 'building blocks'
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals reported a second consecutive quarter of 30% revenue growth and a 19% boost in sales for Cubicin (daptomycin), its antibiotic to treat serious infections in hospital settings, marking a strong start to its five-year "Building Blocks of Growth" plan.